Many prostate cancer molecular biomarkers have been identified; however, only a few are Food and Drug Administration (FDA) approved (PSA in 1994, phi in 2012, and PCA3 in 2012) (Table 1). This evidence concerns the gene PCA3 and prostate cancer.